# Cytochrome P450 System Inhibition and Induction

> Cytochrome P450 System: Inhibition, Induction, and Metabolic Activation provides an exhaustive biochemical guide to the primary enzymatic superfamily responsible for drug metabolism, xenobiotic…

Canonical: https://wiki.soapbox.community/wiki/Cytochrome_P450_System_Inhibition_and_Induction
Section: Substances and pharmacology, Organic chemistry and synthesis
Last updated: 2026-09-28
Publisher: Library of Ashurbanipal (Van Kush Family Research Institute), https://wiki.soapbox.community

**Cytochrome P450 System: Inhibition, Induction, and Metabolic Activation** provides an exhaustive biochemical guide to the primary enzymatic superfamily responsible for drug metabolism, xenobiotic clearance, and botanical bioactivation. Cytochrome P450 (CYP450) enzymes govern first-pass intestinal and hepatic clearance, determine the systemic bioavailability of pharmaceuticals and botanical actives, and dictate whether co-administered compounds produce clinical toxicity or therapeutic failure.

This article details the catalytic monooxygenase mechanism, major clinical isoforms, competitive versus mechanism-based suicide inhibition, nuclear receptor transcriptional induction, the critical divergence between prodrugs and active drugs, and the cannabinoid-CYP interface.

## Catalytic biochemistry of the CYP450 superfamily

CYP450 enzymes are membrane-bound hemoproteins anchored to the cytosolic surface of the smooth endoplasmic reticulum in hepatocytes and intestinal enterocytes:

                 [ Substrate: R-H ] + O2 + NADPH + H⁺
                                 │
                                 ▼  CYP450 (Heme Iron Catalysis)
                 [ Product: R-OH ] + H2O + NADP⁺

### The monooxygenase cycle

1. **Substrate binding:** The lipophilic drug molecule ($R\text{-}H$) enters the hydrophobic active pocket and coordinates near the central heme iron ($Fe^{3+}$).
2. **First electron transfer:** NADPH-cytochrome P450 reductase transfers an electron to reduce the iron from ferric ($Fe^{3+}$) to ferrous ($Fe^{2+}$).
3. **Oxygen activation:** Molecular triplet oxygen ($O_2$) binds the ferrous iron. A second electron transfer forms a transient peroxo intermediate, which is protonated to release water ($H_2O$), generating a highly reactive ferryl-oxo radical cation ($\text{Compound I}, [Fe^{IV}=O]^{\bullet+}$).
4. **Hydrogen abstraction and rebound:** The ferryl oxygen abstracts a hydrogen atom from the substrate, forming a transient substrate radical, which immediately recombines ("oxygen rebound") to produce a hydroxylated, polar metabolite ($R\text{-}OH$).

## Major clinical isoforms

Five distinct CYP families handle over 90% of all prescription drugs and psychoactive natural products:

{| class="wikitable"
! Isoform !! Relative liver abundance !! Primary substrates !! Potent inhibitors !! Potent inducers
|-
| **CYP3A4 / 3A5** || ~30% (Handles >50% of all drugs) || Fentanyl, statins, benzodiazepines, ketamine, THC-OH, macrolides || Grapefruit (bergamottin), piperine, ketoconazole, ritonavir, CBD || St. John's Wort (hyperforin), rifampin, carbamazepine, phenytoin
|-
| **CYP2D6** || ~2–4% (High phenotypic variation) || Codeine, tramadol, dextromethorphan, SSRIs, tricyclics, plant allylbenzenes || Fluoxetine, paroxetine, bupropion, piperine, quinidine || Not typically inducible (genetically regulated)
|-
| **CYP1A2** || ~13% || Caffeine, theophylline, melatonin, olanzapine, tacrine || Fluvoxamine, ciprofloxacin || Polycyclic aromatic hydrocarbons (smoking cannabis/tobacco), cruciferous vegetables
|-
| **CYP2C9** || ~20% || Δ9-THC (conversion to 11-OH-THC), warfarin, phenytoin, NSAIDs || CBD, fluconazole, amiodarone, sulfamethoxazole || Rifampin, St. John's Wort
|-
| **CYP2C19** || ~7% || Clopidogrel (prodrug), omeprazole, diazepam, escitalopram || CBD, fluconazole, fluvoxamine, omeprazole || Rifampin, carbamazepine
|}

## Mechanisms of enzyme inhibition

Inhibition occurs when a co-administered substance suppresses the catalytic turnover of an enzyme, sharply raising or lowering circulating drug levels:

                            [ INHIBITION MODES ]
                                     │
           ┌─────────────────────────┴─────────────────────────┐
           ▼                                                   ▼
[ Competitive / Reversible ]                       [ Mechanism-Based (MBI / Suicide) ]
 • Competes for heme pocket                         • Substrate metabolically converted
 • Rapid onset, concentration-dependent               into reactive electrophilic radical
 • Dissipates as inhibitor clears                   • Covalently destroys heme / apoprotein
                                                    • Requires de novo protein synthesis (days)

### 1. Competitive reversible inhibition

- The inhibitor binds non-covalently within the active catalytic site, competing directly with the substrate.
- Increases the apparent Michaelis constant ($K_m$) without altering maximum velocity ($V_{max}$).
- Onset is rapid, and enzymatic activity recovers immediately once the inhibitor is cleared or displaced by high substrate concentrations.

### 2. Mechanism-Based Inactivation (MBI / "Suicide Inhibition")

- The inhibitor acts as a "pseudosubstrate." The CYP enzyme attempts to metabolize the molecule, but the reaction generates an unstable, reactive electrophilic intermediate.
- This reactive species attacks and forms an irreversible covalent bond with the catalytic heme iron or adjacent apoprotein amino acid residues, permanently destroying catalytic activity:
: CYP + Prodrug/Inhibitor ──► [Reactive Carbene/Radical] ──► Covalent Inactivation
- **Grapefruit Furanocoumarins (Bergamottin and 6',7'-dihydroxybergamottin):** Irreversibly destroy intestinal enterocyte CYP3A4. Recovery requires 48 to 72 hours for the gut epithelium to biosynthesize new CYP3A4 proteins.
- **Piperine (Black Pepper):** Exhibits mechanism-based inactivation of human CYP3A4 and CYP2D6 alongside reversible inhibition, accounting for dramatic systemic exposure surges of co-administered botanicals.

## Mechanisms of enzyme induction

Enzyme induction is the process by which a compound increases the physical concentration of CYP450 enzymes by upregulating gene transcription:

- **Nuclear receptors:** Xenobiotics bind to intracellular nuclear receptors, including the **Pregnane X Receptor (PXR)**, the **Constitutive Androstane Receptor (CAR)**, or the **Aryl Hydrocarbon Receptor (AhR)**.
- **Transcriptional activation:** Upon ligand binding, the receptor forms a heterodimer with the retinoid X receptor (RXR), translocates to the nucleus, and binds response elements in the promoter region of specific CYP genes, accelerating mRNA transcription.
- **Kinetics:** Unlike rapid inhibition, induction is a slow biological process taking several days to weeks to reach maximal expression, and persisting for days after the inducer is discontinued while excess enzymes degrade.
- **St. John's Wort (Hypericum perforatum):** The active constituent **hyperforin** is one of the most potent natural agonists of human PXR, driving massive induction of CYP3A4 and P-glycoprotein. Co-ingestion slashes circulating blood levels of oral contraceptives, cyclosporine, antiretrovirals, and statins, causing widespread clinical failures.
- **Combustion smoke:** Inhaling polycyclic aromatic hydrocarbons (PAHs) from combusted cannabis or tobacco smoke activates AhR, heavily inducing **CYP1A2**. Smokers metabolize caffeine roughly 50% faster than non-smokers.

## The critical divergence: prodrugs vs. active drugs

Whether enzyme modulation causes dangerous toxicity or therapeutic failure depends entirely on whether the target compound is an active drug or a metabolic prodrug:

{| class="wikitable"
! Molecule type !! Standard status !! Effect of CYP INHIBITION !! Effect of CYP INDUCTION
|-
| **Active Drug** (e.g., Fentanyl, Warfarin, Alprazolam) || Active as ingested; CYP enzymes inactivate and clear it. || **Toxicity / Overdose:** Clearance blocked; drug accumulates to toxic plasma levels. || **Subtherapeutic Failure:** Cleared too rapidly; drug fails to reach clinical threshold.
|-
| **Metabolic Prodrug** (e.g., Codeine, Clopidogrel, Psilocybin) || Inactive/less active as ingested; CYP enzymes convert it into active metabolite. || **Therapeutic Failure:** Conversion blocked; parent prodrug cleared without releasing active drug. || **Toxicity / Rapid Surge:** Conversion accelerated; sudden burst of active metabolite.
|}

- **Codeine Example:** Codeine is an inactive prodrug that requires **CYP2D6** to undergo O-demethylation into active morphine. If a patient takes a strong CYP2D6 inhibitor (such as fluoxetine or piperine), codeine cannot convert to morphine and produces zero analgesia. Conversely, a genetic "ultra-rapid metabolizer" converts codeine to morphine rapidly, risking fatal respiratory depression at standard therapeutic doses.

## Cannabinoids and the CYP450 matrix

Phytocannabinoids are both major substrates and potent modulators of hepatic CYP enzymes:

### 1. CBD as a master inhibitor

- Cannabidiol (CBD) is a potent, clinically documented competitive inhibitor of **CYP3A4**, **CYP2C19**, and to a lesser degree CYP2D6.
- High clinical doses of oral CBD (such as Epidiolex) significantly raise serum levels of the anti-epileptic clobazam (via CYP2C19 inhibition) and elevate blood levels of warfarin, requiring clinical dosage reductions.

### 2. THC metabolic activation

- Ingested Δ9-THC undergoes extensive first-pass hepatic metabolism:
: Δ9-THC ──(CYP2C9 / CYP3A4)──► 11-Hydroxy-Δ9-THC (11-OH-THC) ──(CYP2C9)──► 11-Nor-9-carboxy-THC
- **11-OH-THC:** Significantly more potent than Δ9-THC at crossing the blood-brain barrier and possesses higher intrinsic efficacy at the CB1 receptor, explaining why oral cannabis edibles produce a markedly heavier, longer-lasting, and more psychedelic experience than inhaled cannabis.

See also: The Expanded Endocannabinoid System and FAAH Science · Cannabinoid Oilahuasca · Black Pepper · Cannabis Harm Reduction · Shulgin Ten Essential Amphetamines and Metabolic Chemistry · Stack Substances